Nhắm mục tiêu vào SMYD2 ức chế sự hình thành mạch và tăng cường hiệu quả của apatinib bằng cách ức chế EGFL7 trong ung thư đại trực tràng

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70(3):145–164. https://doi.org/10.3322/caac.21601 Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186 Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6):713–718. https://doi.org/10.1634/theoncologist.12-6-713 Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F, Generali D (2016) Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett 372(2):187–191. https://doi.org/10.1016/j.canlet.2016.01.014 Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Hartel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP (2019) Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine 45:139–154. https://doi.org/10.1016/j.ebiom.2019.07.004 Goel A, Boland CR (2012) Epigenetics of colorectal cancer. Gastroenterology 143(6):1442–1460. https://doi.org/10.1053/j.gastro.2012.09.032 Brown MA, Sims RJ 3rd, Gottlieb PD, Tucker PW (2006) Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol Cancer 5:26. https://doi.org/10.1186/1476-4598-5-26 Abu-Farha M, Lambert JP, Al-Madhoun AS, Elisma F, Skerjanc IS, Figeys D (2008) The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase. Mol Cell Proteomics 7(3):560–572. https://doi.org/10.1074/mcp.M700271-MCP200 Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL (2006) Repression of p53 activity by Smyd2-mediated methylation. Nature 444(7119):629–632. https://doi.org/10.1038/nature05287 Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, Ponder BA, Yamaue H, Nakamura Y, Hamamoto R (2012) RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 14(6):476–486. https://doi.org/10.1593/neo.12656 Zeng Y, Qiu R, Yang Y, Gao T, Zheng Y, Huang W, Gao J, Zhang K, Liu R, Wang S, Hou Y, Yu W, Leng S, Feng D, Liu W, Zhang X, Wang Y (2019) Regulation of EZH2 by SMYD2-mediated lysine methylation is implicated in tumorigenesis. Cell Rep 29(6):1482–1498. https://doi.org/10.1016/j.celrep.2019.10.004 Hamamoto R, Toyokawa G, Nakakido M, Ueda K, Nakamura Y (2014) SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation. Cancer Lett 351(1):126–133. https://doi.org/10.1016/j.canlet.2014.05.014 Obermann WMJ (2018) A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor alpha methylation by the lysine methyltransferase SMYD2. J Biol Chem 293(42):16479–16487. https://doi.org/10.1074/jbc.RA118.003578 Nakakido M, Deng Z, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R (2015) Dysregulation of AKT pathway by SMYD2-mediated lysine methylation on PTEN. Neoplasia 17(4):367–373. https://doi.org/10.1016/j.neo.2015.03.002 Piao L, Kang D, Suzuki T, Masuda A, Dohmae N, Nakamura Y, Hamamoto R (2014) The histone methyltransferase SMYD2 methylates PARP1 and promotes polyADP-ribosylation activity in cancer cells. Neoplasia 16(3):257–264. https://doi.org/10.1016/j.neo.2014.03.002 Egorova KS, Olenkina OM, Olenina LV (2010) Lysine methylation of nonhistone proteins is a way to regulate their stability and function. Biochemistry (Mosc) 75(5):535–548. https://doi.org/10.1134/s0006297910050019 Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, Ye Z, Xing J, Xiao K, Wu L, Xu H (2019) Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. Theranostics 9(26):8377–8391. https://doi.org/10.7150/thno.37628 Meng F, Liu X, Lin C, Xu L, Liu J, Zhang P, Zhang X, Song J, Yan Y, Ren Z, Zhang Y (2020) SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer. Am J Cancer Res 10(3):997–1011 Creamer D, Allen MH, Sousa A, Poston R, Barker JN (1997) Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 136(6):859–865 Fan C, Yang LY, Wu F, Tao YM, Liu LS, Zhang JF, He YN, Tang LL, Chen GD, Guo L (2013) The expression of Egfl7 in human normal tissues and epithelial tumors. Int J Biol Markers 28(1):71–83. https://doi.org/10.5301/jbm.2013.10568 Nichol D, Shawber C, Fitch MJ, Bambino K, Sharma A, Kitajewski J, Stuhlmann H (2010) Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood 116(26):6133–6143. https://doi.org/10.1182/blood-2010-03-274860 Xu Y, Wu W, Han Q, Wang Y, Li C, Zhang P, Xu H (2019) Post-translational modification control of RNA-binding protein hnRNPK function. Open Biol 9(3):180239. https://doi.org/10.1098/rsob.180239 Lv Y, Shi Y, Han Q, Dai G (2017) Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro. Mol Med Rep 16(4):4437–4444. https://doi.org/10.3892/mmr.2017.7130 Liu Q, Pang J, Wang LA, Huang Z, Xu J, Yang X, Xie Q, Huang Y, Tang T, Tong D, Liu G, Wang L, Zhang D, Ma Q, Xiao H, Lan W, Qin J, Jiang J (2021) Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. J Pathol 253(1):106–118. https://doi.org/10.1002/path.5557 Feng W, Yonezawa M, Ye J, Jenuwein T, Grummt I (2010) PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat Struct Mol Biol 17(4):445–450. https://doi.org/10.1038/nsmb.1778 Zhang H (2015) Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther 9:6075–6081. https://doi.org/10.2147/DDDT.S97235 Huang G, Chen L (2008) Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm 23(5):661–667. https://doi.org/10.1089/cbr.2008.0492 Viallard C, Larrivee B (2017) Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20(4):409–426. https://doi.org/10.1007/s10456-017-9562-9 Hong G, Kuek V, Shi J, Zhou L, Han X, He W, Tickner J, Qiu H, Wei Q, Xu J (2018) EGFL7: master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. J Cell Physiol 233(11):8526–8537. https://doi.org/10.1002/jcp.26792 Usuba R, Pauty J, Soncin F, Matsunaga YT (2019) EGFL7 regulates sprouting angiogenesis and endothelial integrity in a human blood vessel model. Biomaterials 197:305–316. https://doi.org/10.1016/j.biomaterials.2019.01.022 Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H (2004) Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn 230(2):316–324. https://doi.org/10.1002/dvdy.20063 Nichol D, Stuhlmann H (2012) EGFL7: a unique angiogenic signaling factor in vascular development and disease. Blood 119(6):1345–1352. https://doi.org/10.1182/blood-2011-10-322446 Richter A, Alexdottir MS, Magnus SH, Richter TR, Morikawa M, Zwijsen A, Valdimarsdottir G (2019) EGFL7 mediates BMP9-induced sprouting angiogenesis of endothelial cells derived from human embryonic stem cells. Stem cell reports 12(6):1250–1259. https://doi.org/10.1016/j.stemcr.2019.04.022 Ostareck-Lederer A, Ostareck DH, Cans C, Neubauer G, Bomsztyk K, Superti-Furga G, Hentze MW (2002) c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol Cell Biol 22(13):4535–4543. https://doi.org/10.1128/mcb.22.13.4535-4543.2002 Gal J, Chen J, Na DY, Tichacek L, Barnett KR, Zhu H (2019) The acetylation of lysine-376 of G3BP1 regulates RNA binding and stress GRANULE Dynamics. Mol Cell Biol. https://doi.org/10.1128/mcb.00052-19 Arenas A, Chen J, Kuang L, Barnett KR, Kasarskis EJ, Gal J, Zhu H (2020) Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS. Hum Mol Genet 29(16):2684–2697. https://doi.org/10.1093/hmg/ddaa159 Wei HM, Hu HH, Chang GY, Lee YJ, Li YC, Chang HH, Li C (2014) Arginine methylation of the cellular nucleic acid binding protein does not affect its subcellular localization but impedes RNA binding. FEBS Lett 588(9):1542–1548. https://doi.org/10.1016/j.febslet.2014.03.052 Wu Z, Connolly J, Biggar KK (2017) Beyond histones - the expanding roles of protein lysine methylation. FEBS J 284(17):2732–2744. https://doi.org/10.1111/febs.14056 Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y, Yang Z, Barton MC, Wen H, Shi X (2013) Regulation of estrogen receptor alpha by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci USA 110(43):17284–17289. https://doi.org/10.1073/pnas.1307959110 Bagislar S, Sabò A, Kress TR, Doni M, Nicoli P, Campaner S, Amati B (2016) Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis. Oncotarget 7(41):66398–66415. https://doi.org/10.18632/oncotarget.12012 Scott AJ, Messersmith WA, Jimeno A (2015) Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc) 51(4):223–229. https://doi.org/10.1358/dot.2015.51.4.2320599 Li A, Wang K, Xu A, Wang G, Miao Y, Sun Z, Zhang J (2019) Apatinib as an optional treatment in metastatic colorectal cancer. Medicine (Baltimore) 98(35):e16919. https://doi.org/10.1097/MD.0000000000016919 Cheng X, Feng H, Wu H, Jin Z, Shen X, Kuang J, Huo Z, Chen X, Gao H, Ye F, Ji X, Jing X, Zhang Y, Zhang T, Qiu W, Zhao R (2018) Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer. Cancer Lett 431:105–114. https://doi.org/10.1016/j.canlet.2018.05.046 Tian X, Li S, Ge G (2021) Apatinib promotes ferroptosis in colorectal cancer cells by targeting ELOVL6/ACSL4 signaling. Cancer Manag Res 13:1333–1342. https://doi.org/10.2147/CMAR.S274631 Yang QK, Chen T, Wang SQ, Zhang XJ, Yao ZX (2020) Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis 23(3):279–298. https://doi.org/10.1007/s10456-020-09716-y Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, Shi K, Yan YC, Yan LJ, Yao CY, Chen ZQ, Zhi XT, Li T (2020) TMPRSS4 drives angiogenesis in hepatocellular carcinoma by promoting HB-EGF expression and proteolytic cleavage. Hepatology 72(3):923–939. https://doi.org/10.1002/hep.31076 Ye G, Zhang J, Zhang C (2021) Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma. Aging 13(16):20793–20807. https://doi.org/10.18632/aging.203475 Shi J, Li Y, Jia R, Fan X (2020) The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance. Int J Cancer 146(8):2078–2088. https://doi.org/10.1002/ijc.32662